Oncotice (Bacillus Calmette-Guérin (Bcg), Tice)

The Bacillus Calmette‑Guérin (BCG) bacteria in Oncotice adhere to the bladder lining and are taken up by immune cells. This initiates a cascade of immune activation, recruiting macrophages, dendritic cells, and T‑lymphocytes, and releasing cytokines that create an inflammatory environment hostile to cancer cells, leading to their destruction.

The specific dose and treatment schedule of Oncotice are determined by the prescribing physician based on the patient’s clinical condition, disease stage, and response to therapy. Healthcare professionals follow established guidelines and adjust the regimen as needed.

Oncotice is not recommended for use during pregnancy or while breastfeeding because safety data are limited. Women of childbearing potential should use effective contraception during treatment, and the drug should be avoided in pregnant or nursing patients unless the potential benefit justifies the risk.

To order Oncotice, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

Oncotice (BCG) is a live bacterial vaccine that provides immunologic control of bladder cancer, whereas intravesical chemotherapy agents act directly on tumor cells without stimulating immunity. BCG has a well‑established record for reducing recurrence in high‑risk non‑muscle invasive disease, but it may have a higher incidence of immune‑related side effects compared with chemotherapeutic options.

Oncotice must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging to maintain stability and potency until it is prepared for intravesical administration.

Oncotice is administered intravesically, meaning the sterile suspension is directly instilled into the bladder through a catheter. The patient typically retains the solution for a prescribed dwell time, usually around two hours, under the supervision of a qualified healthcare professional.

The most serious risks include systemic BCG infection or sepsis, disseminated mycobacterial disease, severe allergic reactions such as anaphylaxis, and bladder contracture leading to reduced bladder capacity. Patients should be monitored closely for fever, chills, persistent urinary symptoms, or signs of systemic infection.

Oncotice should not be used in patients with active urinary tract infection, severe immunosuppression (e.g., HIV/AIDS with low CD4 counts, high‑dose steroids), those who have received systemic chemotherapy within two weeks of treatment, or individuals who are pregnant or breastfeeding. Contra‑indications are assessed by the prescribing clinician.